Krystal Biotech Inc (KRYS)
183.64
+0.77
(+0.42%)
USD |
NASDAQ |
Jun 28, 16:00
183.61
-0.03
(-0.02%)
After-Hours: 20:00
Krystal Biotech SG&A Expense (Annual): 98.40M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 98.40M |
| December 31, 2022 | 77.74M |
| December 31, 2021 | 40.39M |
| December 31, 2020 | 15.06M |
| Date | Value |
|---|---|
| December 31, 2019 | 6.465M |
| December 31, 2018 | 4.155M |
| December 31, 2017 | 1.564M |
| December 31, 2016 | 0.402M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
6.465M
Minimum
2019
98.40M
Maximum
2023
47.61M
Average
40.39M
Median
2021
SG&A Expense (Annual) Benchmarks
| Biomarin Pharmaceutical Inc | 937.30M |
| Integra Lifesciences Holdings Corp | 656.64M |
| OraSure Technologies Inc | 94.51M |
| Madrigal Pharmaceuticals Inc | 108.15M |
| Agios Pharmaceuticals Inc | 119.90M |